Dupixent Succeeds Where Other Biologic Drugs Failed – In COPD
Efficacy In Phase III Trial Exceeded Expectations
Sanofi and Regeneron could be poised to add another blockbuster indication to the IL-4/IL-13 inhibitor, for chronic obstructive pulmonary disease.
